Value of growth differentiation factor-15 in predicting risk of acute kidney injury in patients with acute coronary syndrome
-
摘要: 目的 评估生长分化因子-15(GDF-15)对急性冠状动脉综合征(ACS)患者住院期间急性肾损伤(AKI)风险的预测价值。 方法 选取694例ACS患者作为研究对象,所有患者入院时留取静脉血,采用酶联免疫吸附法(ELISA)测定GDF-15水平,根据住院后是否发生AKI将患者分为实验组(AKI组)81例与对照组(非AKI组)613例。比较2组患者GDF-15水平,采用多因素Logistic回归分析评估GDF-15水平与ACS患者住院期间AKI风险的相关性,并采用受试者工作特征(ROC)曲线评估GDF-15对AKI风险的预测价值。 结果 694例ACS患者的AKI发生率为11.67%; 实验组患者入院时GDF-15水平为(1 320.24±281.71)ng/L, 高于对照组的(979.88±319.77)ng/L, 差异有统计学意义(P<0.05); GDF-15高表达是ACS患者住院期间发生AKI的独立危险因素(OR值为1.004, 95%CI为1.003~1.005, P<0.001); 血清GDF-15水平预测AKI风险的ROC曲线下面积(AUC)为0.774, 95%CI为0.723~0.824。 结论 高水平GDF-15是ACS患者住院期间AKI风险的独立危险因素,对AKI风险具有较高的预测价值。Abstract: Objective To evaluate the value of growth differentiation factor-15(GDF-15)in predicting risk of acute kidney injury(AKI)in patients with acute coronary syndrome(ACS). Methods Totally 694 ACS patients were enrolled as research objects. Venous blood of all patients were collected at the time of admission. The expression levels of GDF-15 were measured by enzyme-linked immunosorbent assay(ELISA). The patients were divided into experimental group(AKI group, n=81)and control group(non-AKI group, n=613)according occurrence of AKI. GDF-15 levels between the two groups were compared. Multivariate logistic regression analysis was performed to analyze correlation between GDF-15 level and AKI risk during hospitalization in ACS patients. The receiver operating characteristic(ROC)curve was used to evaluate the predictive value of GDF-15 in AKI risk. Results The occurrence of AKI in 694 patients was 11.67%. GDF-15 level at admission in the experimental group was higher than that in the control group ［(1 320.24±281.71)versus(979.88±319.77)ng/L, P<0.05］. High expression of GDF-15 was an independent risk factor of AKI in ACS patients during hospitalization(OR: 1.004, 95% confidence interval(CI): 1.003-1.005, P<0.001). The area under the curves(AUC)of plasma GDF-15 was 0.774, with 95% CI of 0.723 to 0.824. Conclusion High level of GDF-15 is an independent risk factor of AKI in ACS patients, which has a higher predictive value for AKI.
-
-
GUPTA R, GURM H S, BHATT D L, et al. Renal failure after percutaneous coronary intervention is associated with high mortality[J]. Catheter Cardiovasc Interv, 2005, 64(4): 442-448.
KATSIKI N, ATHYROS V G, KARAGIANNIS A, et al. Contrast-induced nephropathy[J]. Angiology, 2015, 66(6): 508-513.
LAMEIRE N, KELLUM J A, KDIGO AKI Guideline Work Group. Contrast-induced acute kidney injury and renal support for acute kidney injury: a KDIGO summary(Part 2)[J]. Crit Care, 2013, 17(1): 205.
GROSSMAN P M, ALI S S, ARONOW H D, et al. Contrast-induced nephropathy in patients undergoing endovascular peripheral vascular intervention: Incidence, risk factors, and outcomes as observed in the Blue Cross Blue Shield of Michigan Cardiovascular Consortium[J]. J Interv Cardiol, 2017, 30(3): 274-280.
MCCULLOUGH P A, ADAM A, BECKER C R, et al. Epidemiology and prognostic implications of contrast-induced nephropathy[J]. Am J Cardiol, 2006, 98(6A): 5K-13K.
MCCULLOUGH P A, ADAM A, BECKER C R, et al. Risk prediction of contrast-induced nephropathy[J]. Am J Cardiol, 2006, 98(6A): 27K-36K.
HERINGLAKE M, CHARITOS E I, ERBER K, et al. Preoperative plasma growth-differentiation factor-15 for prediction of acute kidney injury in patients undergoing cardiac surgery[J]. Crit Care, 2016, 20(1): 317.
ZHANG W, CHU H C, XUE F. Assessing preoperative plasma growth-differentiation factor-15 for prediction of acute kidney injury in patients undergoing cardiac surgery[J]. Crit Care, 2017, 21(1): 53.
NISHIO E, WATANABE Y. Transforming growth factor beta is a modulator of platelet-derived growth factor action in vascular smooth muscle cells: a possible role for catalase activity and glutathione peroxidase activity[J]. Biochem Biophys Res Commun, 1997, 232(1): 1-4.
WALLENTIN L, HIJAZI Z, ANDERSSON U, et al. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation(ARISTOTLE)trial[J]. Circulation, 2014, 130(21): 1847-1858.
KEMPF T, EDEN M, STRELAU J, et al. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury[J]. Circ Res, 2006, 98(3): 351-360.
SUN L, WANG Q. Mid-term prognostic value of serum growth differentiation factor-15 in patients with acute coronary syndrome[J]. Chinese Journal of Arteriosclerosis, 2017, 25: 505-508.
HAGSTRÖM E, HELD C, STEWART R A, et al. Growth differentiation factor 15 predicts all-cause morbidity and mortality in stable coronary heart disease[J]. Clin Chem, 2017, 63(1): 325-333.
EGGERS K M, KEMPF T, LAGERQVIST B, et al. Growth-differentiation factor-15 for long-term risk prediction in patients stabilized after an episode of non-ST-segment-elevation acute coronary syndrome[J]. Circ Cardiovasc Genet, 2010, 3(1): 88-96.
KEMPF T, BJÖRKLUND E, OLOFSSON S, et al. Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction[J]. Eur Heart J, 2007, 28(23): 2858-2865.
EGGERS K M, KEMPF T, WALLENTIN L, et al. Change in growth differentiation factor 15 concentrations over time independently predicts mortality in community-dwelling elderly individuals[J]. Clin Chem, 2013, 59(7): 1091-1098.
SUN L, ZANG X, SONG Y, et al. Relations between growth differentiation factor-15 and no-reflow in patients with acute myocardial infarction[J]. Chinese Journal of Arteriosclerosis, 2017, 26: 599-603.
WOLLERT K C, KEMPF T, WALLENTIN L. Growth differentiation factor 15 as a biomarker in cardiovascular disease[J]. Clin Chem, 2017, 63(1): 140-151.
KAHLI A, GUENANCIA C, ZELLER M, et al. Growth differentiation factor-15(GDF-15)levels are associated with cardiac and renal injury in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass[J]. PLoS One, 2014, 9(8): e105759.
-
期刊类型引用(3)
1. 王永庆，蔡学礼，黄良通. 神经介入联合小剂量替罗非班在缺血性卒中患者中的应用. 中国医师杂志. 2024(09): 1423-1426 . 
百度学术
2. 赵建彬，赵玮康. 双负荷剂量氯吡格雷联合阿司匹林治疗急性脑梗死的疗效研究. 中国合理用药探索. 2023(09): 73-77 . 百度学术
3. 陈莉，钟华. 阿替普酶静脉溶栓联合替罗非班及双抗治疗内囊预警综合征1例报道. 心脑血管病防治. 2022(05): 102-104 . 百度学术
其他类型引用(0)
计量
- 文章访问数: 429
- HTML全文浏览量: 103
- PDF下载量: 7
- 被引次数: 3
下载:
苏公网安备 32100302010246号
